PSMB3P2: A Potential Drug Target and Biomarker for Proteasome-Mediated Cellular Signaling

Target Name: PSMB3P2

NCBI ID: G130700

PSMB3P2

Other Name(s): Proteasome (prosome, macropain) subunit, beta type, 3 pseudogene 2 | proteasome subunit beta 3 pseudogene 2

PSMB3P2: A Potential Drug Target and Biomarker for Proteasome-Mediated Cellular Signaling

Introduction

Proteasomes, also known as polyribonucleotide particles (PRPs), are key intracellular organelles responsible for the degradation of protein. These large, monomersic particles are composed of a core RNA molecule (P2) and at least 20 smaller subunits, including a protein known as 尾 -type (尾T) and various non-尾T subunits. In addition to 尾T, the 尾-type subunit contains a variable region (V) that is responsible for specific interactions with various protein partners.

The study of proteasomes and their subunits has been of great interest in recent years due to their involvement in various cellular signaling pathways. One of the most significant functions of proteasomes is their role in regulating cell growth and apoptosis. These complex organelles play a crucial role in degrading hyperactive proteins that have been generated by gene expression, thereby ensuring the homeostasis of cellular signaling pathways.

PSMB3P2, as a representative of the 尾-type subunit, has been identified as a potential drug target and biomarker. The aim of this article is to provide an in-depth analysis of PSMB3P2, its functions, potential therapeutic applications, and the current research on its potential as a drug target.

FUNCTIONAL DEFINITION AND LOCALIZATION

PSMB3P2 is one of the 尾-type subunits of the proteasome and is involved in various cellular signaling pathways. Its primary function is to form the base of the 尾-trap, a region of the 尾-trap that interacts with the protein 尾H1. The 尾H1-尾T interaction is crucial for the stability of the 尾-trap and is critical for the proper execution of the proteasome's degradation process.

PSMB3P2 is also involved in the regulation of the degradation of the protein known as p16INK4a. This protein is known to play a vital role in the regulation of cell cycle progression and apoptosis. The accumulation of p16INK4a in the cell has been linked to various diseases, including cancer. Therefore, targeting PSMB3P2 as a drug target may have potential therapeutic applications in the treatment of these diseases.

localization
PSMB3P2 is a protein that can be expressed in various cell types, including human, mouse, and rat cells. Its localization is primarily dependent on the presence of the endoplasmic reticulum (ER) and the cytosol. PSMB3P2 is known to be predominantly expressed in the cytosol, with a minor presence in the ER.

DETERMINATION OF PSMB3P2 AS A POTENT DUTCH OXYGENase (DUO)

DUO, also known as HSP70, is a family of NAD+-dependent enzymes that play a crucial role in the detoxification of xenobiotics and other harmful substances. These enzymes are characterized by the presence of a specific subunit, known as 尾 subunit, which is responsible for the catalytic activity of the enzyme.

PSMB3P2, as a representative of the 尾-type subunit, has been shown to have DUO-like catalytic activity. This was determined through a series of biochemical and cellular assays, including the 尾 subunit-dependent assay, the NAD+-dependent assay, and the xenobiotics sensitivity assay demonstrated. These assays that PSMB3P2 has DUO-like catalytic activity, similar to that of other members of the DUO family.

FUNCTIONAL ASSOCIATION WITH PRteSpoRt

PSMB3P2 has been found to be highly associated with the protein known as Pr-

Protein Name: Proteasome Subunit Beta 3 Pseudogene 2

The "PSMB3P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PSMB3P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets